2-Bromoethanol

2-Bromoethanol

SCHEMBL787320

OCCBr.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.60
CYP3A4 P08684 1/20 0.60
ESR1 P03372 4/20 0.52
ESR2 Q92731 4/20 0.52
GAA P10253 2/20 0.37
KDM4E B2RXH2 1/20 0.37
TSHR P16473 3/20 0.36
ALDH1A1 P00352 2/20 0.36
TRPA1 O75762 1/20 0.36
PTPN1 P18031 2/20 0.34
GSK3B P49841 2/20 0.34
RECQL P46063 1/20 0.34
HPGD P15428 1/20 0.32
CES2 O00748 2/20 0.32
CES1 P23141 2/20 0.32
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3117767 0.89 TDP1 (0.52) TDP1CYP3A4ESR1ESR2GAA
1,2-Dibromoethane SCHEMBL28837174 0.87 TDP1 (0.71) TDP1CYP3A4ESR1ESR2GAA
SCHEMBL3367511 0.85 TDP1 (0.48) TDP1CYP3A4ESR1ESR2GAA
Dibromomethane SCHEMBL5329477 0.84 TDP1 (0.75) TDP1CYP3A4ESR1ESR2GAA
Dibromomethane SCHEMBL7950072 0.84 TDP1 (0.75) TDP1CYP3A4ESR1ESR2GAA
SCHEMBL319391 0.82 TDP1 (0.63) TDP1CYP3A4ESR1ESR2GAA
SCHEMBL5453551 0.82 TDP1 (0.63) TDP1CYP3A4ESR1ESR2GAA
Ethylene Glycol SCHEMBL25311579 0.81 TDP1 (0.48) TDP1CYP3A4ESR1ESR2GAA
Propanol SCHEMBL16974060 0.80 TDP1 (0.60) TDP1CYP3A4ESR1ESR2GAA
N-Propyl Bromide SCHEMBL1400032 0.80 TDP1 (0.60) TDP1CYP3A4ESR1ESR2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-7173002-A None JP disclosed
CN-118613472-A Nicotinamide ester and nicotinamide riboside-based compounds and derivatives thereof 新前沿生物公司 2024-09-06 CN disclosed
CN-118019801-A Fluoropolymer compositions and methods of making the same 阿科玛股份有限公司 2024-05-10 CN disclosed
US-20230097440-A1 METHODS FOR MODULATION OF LIPOPROTEIN LIPASE AND APOLIPOPROTEIN C2 EXPRESSION AND/OR ACTIVITY IN THE TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM TISSUE DISEASE STATES ENDECE LLC 2023-03-30 US disclosed
CN-113863022-A Colored coating and artificial leather 美利肯公司 2021-12-31 CN disclosed
CN-112318797-A Colored coating and artificial leather comprising a colorant complex 美利肯公司 2021-02-05 CN disclosed
US-20210024568-A1 METHODS FOR MODULATION OF LIPOPROTEIN LIPASE AND APOLIPOPROTEIN C2 EXPRESSION AND/OR ACTIVITY IN THE TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM TISSUE DISEASE STATES ENDECE LLC 2021-01-28 US disclosed
US-10723757-B2 6-substituted estradiol derivatives and methods of use ENDECE LLC (US) 2020-07-28 US disclosed
US-20190135853-A1 6-Substituted Estradiol Derivatives and Methods of Use ENDECE LLC 2019-05-09 US disclosed
US-10174070-B2 6-substituted estradiol derivatives and methods of use ENDECE LLC (US) 2019-01-08 US disclosed
EP-2616477-B1 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS ER-BETA AGONISTS ENDECE LLC (US) 2016-11-09 EP disclosed
US-20160279144-A1 6-Substituted Estradiol Derivatives for Use in Remyelination of Nerve Axons ENDECE LLC 2016-09-29 US disclosed
EP-2507253-B1 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE ENDECE LLC (US) 2016-03-30 EP disclosed
EP-2688570-B1 6-SUBSTITUTED ESTRADIOL DERIVATIVES FOR USE IN REMYELINATION OF NERVE AXONS ENDECE LLC (US) 2015-11-18 EP disclosed
WO-2015143201-A2 6-SUBSTITUTED ESTRADIOL DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE ENDECE LLC (US) 2015-09-24 WO disclosed
EP-2688570-A2 6-SUBSTITUTED ESTRADIOL DERIVATIVES FOR USE IN REMYELINATION OF NERVE AXONS Endece, LLC (US) 2014-01-29 EP disclosed
EP-2616477-A2 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS ER-BETA AGONISTS Endece, LLC (US) 2013-07-24 EP disclosed
WO-2012129324-A2 6-SUBSTITUTED ESTRADIOL DERIVATIVES FOR USE IN REMYELINATION OF NERVE AXONS ENDECE LLC (US) 2012-09-27 WO disclosed
WO-2012037261-A2 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS ER-BETA AGONISTS ENDECE, LLC (US) 2012-03-22 WO disclosed
JP-H07173002-A SEX ATTRACTANT FOR ANOMALA SCONFELDTI NORIN SUISANSYO SANSHI KONCHIYUU NOGYO GIJUTSU KENKYUSHO 1995-07-11 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723757-B2 6-substituted estradiol derivatives and methods of use SHBG, HSD17B11, CYP19A1 TDP1 2410/4885CYP3A4 64/4885ESR1 5/4885
US-20190135853-A1 6-Substituted Estradiol Derivatives and Methods of Use SHBG, HSD17B11, CYP19A1 TDP1 2410/4885CYP3A4 64/4885ESR1 5/4885
US-20230097440-A1 METHODS FOR MODULATION OF LIPOPROTEIN LIPASE AND APOLIPOPROTEIN C2 EXPRESSION AND/OR ACTIVITY IN THE TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM TISSUE DISEASE STATES LPL, LIPE, PMP22 TDP1 1047/4885CYP3A4 2184/4885ESR1 623/4885
US-10174070-B2 6-substituted estradiol derivatives and methods of use NR3C2, SHBG, NR5A1 TDP1 4863/4885CYP3A4 587/4885ESR1 17/4885
US-20160279144-A1 6-Substituted Estradiol Derivatives for Use in Remyelination of Nerve Axons PMP22, GAP43, MAG TDP1 2639/4885CYP3A4 2566/4885ESR1 199/4885
US-20210024568-A1 METHODS FOR MODULATION OF LIPOPROTEIN LIPASE AND APOLIPOPROTEIN C2 EXPRESSION AND/OR ACTIVITY IN THE TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM TISSUE DISEASE STATES LPL, LIPE, PMP22 TDP1 1047/4885CYP3A4 2184/4885ESR1 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.